ADC Therapeutics SA
ADCT
$3.10
-$0.01-0.32%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -56.65M | -38.60M | -30.73M | -43.97M | -36.54M |
| Total Depreciation and Amortization | 840.00K | 801.00K | 793.00K | 802.00K | 838.00K |
| Total Amortization of Deferred Charges | 650.00K | 191.00K | -557.00K | 516.00K | 440.00K |
| Total Other Non-Cash Items | 15.72M | 10.79M | -1.39M | 9.07M | 7.24M |
| Change in Net Operating Assets | 15.35M | -29.52M | 10.03M | 8.54M | -4.82M |
| Cash from Operations | -24.09M | -56.33M | -21.85M | -25.04M | -32.85M |
| Capital Expenditure | 0.00 | -264.00K | -90.00K | -216.00K | -30.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | -264.00K | -90.00K | -216.00K | -30.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 94.03M | 271.00K | 43.00K | -- | 98.70M |
| Repurchase of Common Stock | -250.00K | -- | -1.16M | -879.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 93.78M | 271.00K | -1.12M | -879.00K | 98.70M |
| Foreign Exchange rate Adjustments | 163.00K | 161.00K | -343.00K | 291.00K | 12.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 69.86M | -56.17M | -23.41M | -25.85M | 65.83M |